Growth hormone and neurofibromatosis.
Howell, Simon J Wilton, Patrick Lindberg, Anders Shalet, Stephen M
Howell, Simon J
Wilton, Patrick
Lindberg, Anders
Shalet, Stephen M
Citations
Altmetric:
Abstract
Data collected from 102 neurofibromatosis (NF) children with growth hormone (GH) deficiency (GHD) who were receiving GH replacement therapy were reviewed to assess the efficacy and safety of GH therapy in this condition. GH was administered at a mean dose of 0. 18 mg/kg/week. During the 1st year the median height velocity increased significantly from 4.2 cm/year before treatment to 7.1 cm/year, and the median height standard deviation score increased from -2.4 to -1.9. The response to therapy, however, was not as good as that observed in patients with idiopathic GHD. GH therapy did not influence the progression of any of the features of NF, including intracranial tumours, and was not associated with an excess of other adverse events. We conclude that GH treatment of NF patients with GHD is beneficial in terms of improved growth rate and is well tolerated.
Description
Date
2000
Publisher
Collections
Keywords
Type
Article
Citation
Growth hormone and neurofibromatosis. 2000, 53 Suppl 1:70-6 Horm. Res.